<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03184870</url>
  </required_header>
  <id_info>
    <org_study_id>CV202-103</org_study_id>
    <secondary_id>2017-001725-40</secondary_id>
    <nct_id>NCT03184870</nct_id>
  </id_info>
  <brief_title>A Study of BMS-813160 in Combination With Chemotherapy or Nivolumab in Patients With Advanced Solid Tumors</brief_title>
  <official_title>A Phase 1b/2 Study of BMS-813160 in Combination With Chemotherapy or Nivolumab in Patients With Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the safety profile, tolerability, PK, PD, and preliminary efficacy
      of BMS-813160 in combination with either chemotherapy or nivolumab in participants with
      metastatic colorectal and pancreatic cancers.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 4, 2017</start_date>
  <completion_date type="Anticipated">March 8, 2021</completion_date>
  <primary_completion_date type="Anticipated">March 8, 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse events (AEs)</measure>
    <time_frame>Approximately 4 years</time_frame>
    <description>Measured by incidence of AEs</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Serious adverse events (SAEs)</measure>
    <time_frame>Approximately 4 years</time_frame>
    <description>Measured by incidence of SAEs</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AEs meeting protocol-defined dose limiting toxicity criteria</measure>
    <time_frame>Approximately 6 months</time_frame>
    <description>Measured by incidence of AEs that meet the protocol-defined dose limiting toxicity criteria</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AEs leading to discontinuation</measure>
    <time_frame>Approximately 4 years</time_frame>
    <description>Measured by incidence of AEs leading to discontinuation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Death</measure>
    <time_frame>Approximately 4 years</time_frame>
    <description>Measured by incidence of deaths</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of laboratory abnormalities</measure>
    <time_frame>Approximately 4 years</time_frame>
    <description>Measured by any laboratory test result that is clinically significant or meets the definition of an SAE, any laboratory test result abnormality that required the patient to have study treatment discontinued or interrupted, or any laboratory test result abnormality that required the participant to receive specific corrective therapy</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Electrocardiogram (ECG)</measure>
    <time_frame>Approximately 4 years</time_frame>
    <description>ECGs will be evaluated by the investigator for any clinically significant changes or for changes meeting dose modifying criteria.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Summary measures of vital signs</measure>
    <time_frame>Approximately 4 years</time_frame>
    <description>Including weight, body temperature, respiratory rate, pulse oximetry, seated blood pressure and heart rate.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Objective response rate (ORR)</measure>
    <time_frame>Approximately 4 years</time_frame>
    <description>ORR is defined as the proportion of all treated participants whose Best overall response (BOR) is either complete response or partial response. BOR for a participant will be assessed per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 by investigator</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Median duration of response (DOR)</measure>
    <time_frame>Approximately 4 years</time_frame>
    <description>DOR for a participant with a BOR of CR or PR, is defined as the time between the date of first response and the date of the first objectively documented tumor progression per RECIST v1.1 or death, whichever occurs first</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Progression free survival (PFS) rate</measure>
    <time_frame>At 24 weeks</time_frame>
    <description>PFS for a participant is defined as the time from the first dosing date to the date of first objectively documented disease progression or death due to any cause, whichever occurs first</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum observed plasma concentration (Cmax)</measure>
    <time_frame>Approximately 4 years</time_frame>
    <description>Summary statistics: geometric means and coefficients of variation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of maximum observed plasma concentration (Tmax)</measure>
    <time_frame>Approximately 4 years</time_frame>
    <description>Summary statistics: medians and ranges</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough observed plasma concentration (Ctrough)</measure>
    <time_frame>Approximately 4 years</time_frame>
    <description>Summary statistics to assess attainment of steady state: geometric means and coefficients of variation; plots vs time by dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Observed plasma concentration at the end of the dosing interval (Ctau)</measure>
    <time_frame>Approximately 4 years</time_frame>
    <description>Summary statistics: geometric means and coefficients of variation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration-time curve from time 0 to 8 hours postdose [AUC(0-8)]</measure>
    <time_frame>Approximately 4 years</time_frame>
    <description>Summary statistics: geometric means and coefficients of variation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration-time curve in one dosing interval [AUC(TAU)]</measure>
    <time_frame>Approximately 4 years</time_frame>
    <description>Summary statistics: geometric means and coefficients of variation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent total body clearance (CLT/F)</measure>
    <time_frame>Approximately 4 years</time_frame>
    <description>Summary statistics: geometric means and coefficients of variation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Accumulation index, calculated based on ratio of AUC(TAU) and Cmax at steady state to after the first dose (AI)</measure>
    <time_frame>Approximately 4 years</time_frame>
    <description>Summary statistics: geometric means and coefficients of variation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal clearance (CLR)</measure>
    <time_frame>Approximately 4 years</time_frame>
    <description>Summary statistics: geometric means and coefficients of variation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent urinary recovery over 24 hours corrected for molecular weight (%UR)</measure>
    <time_frame>Approximately 4 years</time_frame>
    <description>Summary statistics: geometric means and coefficients of variation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ratio of metabolite Cmax to parent Cmax, corrected for molecular (MR_Cmax)</measure>
    <time_frame>Approximately 4 years</time_frame>
    <description>Summary statistics: geometric means and coefficients of variation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ratio of metabolite AUC(TAU) to parent AUC(TAU), corrected for molecular weight [MR_AUC(TAU)]</measure>
    <time_frame>Approximately 4 years</time_frame>
    <description>Summary statistics: geometric means and coefficients of variation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of positive anti-drug antibody (ADA) to nivolumab during combination therapy</measure>
    <time_frame>Approximately 4 years</time_frame>
    <description>Frequency distribution of baseline ADA-positive participants and ADA-positive participants after initiation of the treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Decrease in regulatory T cells (Treg) &amp; tumor-associated macrophages (TAM) in tumor samples</measure>
    <time_frame>Approximately 4 years</time_frame>
    <description>Examination of tumor-associated immune cells and microenvironment, through proteomics</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">260</enrollment>
  <condition>Colorectal Cancer</condition>
  <condition>Pancreatic Cancer</condition>
  <arm_group>
    <arm_group_label>Combination Therapy 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BMS-813160 with 5-fluorouracil (5-FU), leucovorin containing regimens in combination with irinotecan</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Combination Therapy 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BMS-813160, nab/paclitaxel and gemcitabine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Combination Therapy 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BMS-813160 and Nivolumab</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Monotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BMS-813160 Monotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-813160</intervention_name>
    <description>specified dose on specified days</description>
    <arm_group_label>Combination Therapy 1</arm_group_label>
    <arm_group_label>Combination Therapy 2</arm_group_label>
    <arm_group_label>Combination Therapy 3</arm_group_label>
    <arm_group_label>Monotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Nivolumab</intervention_name>
    <description>specified dose on specified days</description>
    <arm_group_label>Combination Therapy 3</arm_group_label>
    <other_name>Opdivo</other_name>
    <other_name>BMS-936558</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nab-paclitaxel</intervention_name>
    <description>chemotherapy regimen</description>
    <arm_group_label>Combination Therapy 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <description>chemotherapy regimen</description>
    <arm_group_label>Combination Therapy 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5-fluorouracil (5-FU)</intervention_name>
    <description>chemotherapy regimen</description>
    <arm_group_label>Combination Therapy 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Leucovorin</intervention_name>
    <description>chemotherapy regimen</description>
    <arm_group_label>Combination Therapy 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Irinotecan</intervention_name>
    <description>chemotherapy regimen</description>
    <arm_group_label>Combination Therapy 1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        For more information regarding Bristol-Myers Squibb Clinical Trial participation, please
        visit www.BMSStudyConnect.com

        Inclusion Criteria:

          -  Participants must have metastatic colorectal or pancreatic cancer

          -  Eastern Cooperative Oncology Group (ECOG) performance status of â‰¤1

          -  Ability to swallow pills or capsules

          -  All participants will be required to undergo mandatory pre and on-treatment biopsies

          -  Adequate marrow function

          -  Adequate other organ functions

          -  Ability to comply with study visits, treatment, procedures, PK and PD sample
             collection, and required study follow-up

        Exclusion Criteria:

          -  Histology other than adenocarcinoma (neuroendocrine or acinar cell)

          -  Suspected, known, or progressive CNS metastases (Imaging required only if participants
             are symptomatic)

          -  Participants with active, known or suspected autoimmune disease

          -  Participants with a condition requiring systemic treatment with either corticosteroids
             (&gt; 10 mg daily prednisone equivalents) or other immunosuppressive medications within
             14 days of study treatment administration

          -  Interstitial lung disease that is symptomatic or may interfere with the detection or
             management of suspected treatment-related pulmonary toxicity

          -  Prior treatment with CCR2 and/or CCR5 inhibitors

          -  History of allergy to study treatments or any of its components of the study arm that
             participant is enrolling

        Other protocol defined inclusion/exclusion criteria could apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Recruiting sites have contact information. Please contact the sites directly. If there is no contact information.</last_name>
    <phone>please email:</phone>
    <email>Clinical.Trials@bms.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>First line of the email MUST contain NCT # and Site #.</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Of Alabama At Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mansoor Saleh, Site 0003</last_name>
      <phone>205-996-1403</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>USC Norris Comprehensive Cancer Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Heinz-Josef Lenz, Site 0025</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Usc/Norris Comprehensive Cancer Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Heinz-Josef Lenz, Site 0002</last_name>
      <phone>323-865-0593</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Of Colorado</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephen Leong, Site 0015</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Georgetown University Medical Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Pishvaian, Site 0018</last_name>
      <phone>202-687-9782</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dung Le, Site 0005</last_name>
      <phone>443-287-0002</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site 0023</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hackensack University Medical Center</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martin Gutierrez, Site 0004</last_name>
      <phone>551-996-5900</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anna Varghese, Site 0017</last_name>
      <phone>646-888-4329</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Foundation</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Davendra Sohal, Site 0021</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter O Dwyer, Site 0014</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Thomas Jefferson University</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Atrayee Basu Mallick, Site 0020</last_name>
      <phone>215-503-3367</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Huntsman Cancer Institute</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ignacio Garrido-Laguna, Site 0016</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cross Cancer Institute</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 1Z2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Sawyer, Site 0013</last_name>
      <phone>7809898157</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 4E6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site 0006</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 8L6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site 0012</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Cancer Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 1X6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xueyu Chen, Site 0001</last_name>
      <phone>4169464551</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Besancon Cedex</city>
        <zip>25030</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Lyon Cedex 08</city>
        <zip>69373</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Montpellier</city>
        <zip>34090</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Paris</city>
        <zip>75012</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site 0022</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site 0007</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>France</country>
    <country>Germany</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/MEDWATCH/safety.htm</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <link>
    <url>http://bms.com/studyconnect/Pages/home.aspx</url>
    <description>BMS Clinical Trial Patient Recruiting</description>
  </link>
  <link>
    <url>http://www.bms.com/clinical_trials/Pages/Investigator_inquiry_form.aspx</url>
    <description>Investigator Inquiry Form</description>
  </link>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 9, 2017</study_first_submitted>
  <study_first_submitted_qc>June 9, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 14, 2017</study_first_posted>
  <last_update_submitted>May 21, 2018</last_update_submitted>
  <last_update_submitted_qc>May 21, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 22, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Irinotecan</mesh_term>
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Nivolumab</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

